Q13526 (PIN1_HUMAN) Homo sapiens (Human)
Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 UniProtKBInterProSTRINGInteractive Modelling
163 aa; Sequence (Fasta) ;
13 identical sequences
It is possible new templates exist for this target since these models were created.
Available Structures
125 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| BIVALENT INTERACTIONS OF PIN1 WITH THE C-TERMINAL TAIL OF PKC |
Heteromer P05771; | 100 | ||||
| SOLUTION STRUCTURE OF PIN1 WW DOMAIN COMPLEXED WITH CDC25 PHOSPHOTHREONINE PEPTIDE |
Heteromer P30311; | 100 | ||||
| SOLUTION STRUCTURE OF PIN1 WW DOMAIN COMPLEXED WITH HUMAN TAU PHOSPHOTHREONINE PEPTIDE |
Heteromer P10636; | 100 | ||||
| Structure of the WW domain of PIN1 in complex with a human phosphorylated Smad3 derived peptide |
Heteromer Q15796; | 100 | ||||
| PIN1 WW domain in complex with a phosphorylated CPEB1 derived peptide |
Heteromer Q9BZB8; | 100 | ||||
| 14-3-3 sigma in complex with Pin1 binding site pS72 and covalently bound TCF521-026 |
Heteromer P31947; | 100 | 2×S6B; 8×CA; 2×CL; | |||
| 14-3-3 sigma in complex with Pin1 binding site pS72 |
Heteromer P31947; | 100 | 4×CA; 4×CL; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1012 |
Heteromer P31947; | 100 | 2×TLK; 2×CA; 2×CL; 2×MG; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound PC2046 |
Heteromer P31947; | 100 | 2×TKK; 2×CA; 2×CL; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound PC2068A |
Heteromer P31947; | 100 | 2×TKH; 2×CA; 2×CL; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound PC2068B |
Heteromer P31947; | 100 | 2×TJK; 2×CA; 2×CL; 2×MG; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1014 |
Heteromer P31947; | 100 | 2×SFW; 4×CA; 2×CL; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1013 |
Heteromer P31947; | 100 | 2×SGH; 4×CA; 2×CL; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound TCF521-011 |
Heteromer P31947; | 100 | 2×P5N; 4×CA; 2×CL; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1019 |
Heteromer P31947; | 100 | 2×TL8; 6×CA; 2×CL; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1009 |
Heteromer P31947; | 100 | 2×TJ8; 2×MG; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1017 |
Heteromer P31947; | 100 | 2×TJB; 2×MG; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound TCF521-110 |
Heteromer P31947; | 100 | 2×S9E; 2×CA; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1032 |
Heteromer P31947; | 100 | 6×UPK; 4×GOL; 4×PEG; 2×MG; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1007 |
Heteromer P31947; | 100 | 2×JFS; 2×CA; 2×MG; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1016 |
Heteromer P31947; | 100 | 2×TQK; 2×CA; 2×CL; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1008 |
Heteromer P31947; | 100 | 2×UFH; 4×CA; 2×CL; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1011 |
Heteromer P31947; | 100 | 2×TLQ; 4×CA; 2×CL; 2×NA; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1005 |
Heteromer P31947; | 100 | 2×UG5; 2×CA; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound CV1040 |
Heteromer P31947; | 100 | 2×T85; 4×MG; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1006 |
Heteromer P31947; | 100 | 2×UG2; 2×CL; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1002F1 |
Heteromer P31947; | 100 | 2×UPQ; 2×CA; 2×CL; 4×PEG; | |||
| Ternary complex of 14-3-3 sigma, Pin1pS72 phosphopeptide, and WQ136 |
Heteromer P31947; | 100 | 6×0AW; 2×CL; | |||
| Ternary complex of 14-3-3 sigma, Pin1pS72 phosphopeptide, and WQ162 |
Heteromer P31947; | 100 | 4×09W; 2×CL; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and bound Fusicoccin A |
Heteromer P31947; | 100 | 2×FSC; 2×MG; | |||
| PIN1 PEPTIDYL-PROLYL CIS-TRANS ISOMERASE FROM HOMO SAPIENS | homo-2-mer | 100.0 | 2×ALA; 2×PRO; 2×SO4; 4×1PG; | |||
| Crystal structure of PIN1 in complex with inhibitor C3 | homo-2-mer | 99.31 | 2×A1D9K; 3×SO4; 1×PE3; | |||
| human Pin1 Fip mutant | monomer | 88.89 | 2×1PE; | |||
| STRUCTURAL BASIS FOR THE PHOSPHOSERINE-PROLINE RECOGNITION BY GROUP IV WW DOMAINS | monomer | 100.0 | ||||
| Two-state solution NMR structure of Pin1 bound to peptide pCDC25c | monomer | 100 | ||||
| Two-state solution NMR structure of Pin1 bound to peptide FFpSPR | monomer | 100 | ||||
| Two-state solution NMR structure of Apo Pin1 | monomer | 100 | ||||
| Solution structure of human Pin1 | monomer | 100 | ||||
| Crystal Structure Analysis of human PIN1 | monomer | 98.67 | 1×QT7; 2×SO4; 1×PG4; | |||
| Crystal structure of a mutant PIN1 PEPTIDYL-PROLYL CIS-TRANS ISOMERASE | monomer | 99.35 | 1×SO4; 1×1PG; | |||
| Crystal Structure Analysis of PIN1 | monomer | 98.0 | 1×2PE; 1×GOL; 1×SO4; | |||
| Human Pin1 with cysteine sulfonic acid 113 | monomer | 99.31 | 1×1PG; | |||
| Crystal Structure Analysis of PIN1 | monomer | 98.67 | 1×SO4; | |||
| Human Pin1 complexed with reduced amide inhibitor | monomer | 99.32 | 1×RZD; 1×PE8; | |||
| Prolyl isomerase Pin1 R14A mutant bound with Brd4 peptide | monomer | 99.31 | 1×PE4; 2×SO4; | |||
| Structural and functional insights of directly targeting Pin1 by Epigallocatechin-3-gallate | monomer | 99.31 | 1×SO4; 3×PE4; 2×KDH; | |||
| Structure-guided design of alpha-amino acid-derived Pin1 inhibitors | monomer | 99.31 | 1×12P; 1×4BY; | |||
| Crystal Structure of human Pin1 complexed with a potent covalent inhibitor | monomer | 99.31 | 1×0BF; 1×P33; | |||
| Crystal structure of a mutant PIN1 PEPTIDYL-PROLYL CIS-TRANS ISOMERASE | monomer | 99.35 | 1×SO4; 1×1PG; | |||
| Crystal Structure of human Pin1 complexed with a covalent inhibitor | monomer | 99.31 | 1×J50; 1×PE8; | |||
| Crystal Structure Analysis of human PIN1 | monomer | 99.32 | 1×J2C; 1×PE8; | |||
| Crystal structure of a mutant PIN1 peptidyl-prolyl cis-trans isomerase | monomer | 99.35 | 1×1PG; 1×SO4; | |||
| Human Pin1 bound to cis peptidomimetic inhibitor | monomer | 99.31 | 1×R2Z; 1×PE4; | |||
| Human Pin1 bound to trans peptidomimetic inhibitor | monomer | 99.31 | 1×3TB; 1×PE4; | |||
| Crystal Structure of human PIN1 complexed with covalent inhibitor | monomer | 99.32 | 1×J3X; | |||
| Crystal structure of a mutant PIN1 PEPTIDYL-PROLYL CIS-TRANS ISOMERASE | monomer | 99.35 | 1×SO4; 1×1PG; | |||
| Crystal structure of a mutant PIN1 PEPTIDYL-PROLYL CIS-TRANS ISOMERASE | monomer | 99.35 | 1×SO4; | |||
| Crystal structure of a mutant PIN1 peptidyl-prolyl cis-trans isomerase | monomer | 99.35 | 1×SO4; 1×1PG; | |||
| Crystal structure of a mutant PIN1 peptidyl-prolyl cis-trans isomerase | monomer | 99.35 | 1×SO4; 1×1PG; | |||
| Selective targeting of disease-relevant protein binding domains by O-phosphorylated natural product… | monomer | 99.31 | 1×3T5; 1×P6G; | |||
| human Pin1 bound to D-PEPTIDE | monomer | 99.31 | 1×PE4; | |||
| human Pin1 bound to L-PEPTIDE | monomer | 99.31 | 1×16P; | |||
| Human R14A Pin1 covalently bound to inhibitor 158F10 in P21 21 21 space group | monomer | 99.31 | 1×P33; 6×SO4; | |||
| Human R14A Pin1 covalently bound to inhibitor 164A10 | monomer | 99.31 | 1×A1ACH; 1×P33; 1×DTT; 5×SO4; | |||
| Structure of Pin1 Complex with 18-crown-6 | monomer | 99.31 | 1×SO4; 2×O4B; 1×DTT; | |||
| Human Pin1 with cysteine sulfinic acid 113 | monomer | 99.31 | 1×15P; | |||
| Human R14A Pin1 covalently bound to inhibitor 158D9 | monomer | 99.31 | 1×P33; 1×DTT; 3×SO4; | |||
| Human R14A Pin1 covalently bound to inhibitor 158F10 | monomer | 99.31 | 5×SO4; 1×DTT; 1×P33; | |||
| Human Pin1 with S-hydroxyl-cysteine 113 | monomer | 99.31 | 1×15P; | |||
| DISCOVERY OF CELL-ACTIVE PHENYL-IMIDAZOLE PIN1 INHIBITORS BY STRUCTURE-GUIDED FRAGMENT EVOLUTION | monomer | 99.31 | 1×12P; 1×G14; | |||
| Oxidation-Mediated Inhibition of the Peptidyl-Prolyl Isomerase Pin1 | monomer | 99.31 | 1×PE4; 4×SO4; | |||
| Structure-guided design of alpha-amino acid-derived Pin1 inhibitors | monomer | 99.31 | 1×4D7; 1×12P; | |||
| DISCOVERY OF CELL-ACTIVE PHENYL-IMIDAZOLE PIN1 INHIBITORS BY STRUCTURE-GUIDED FRAGMENT EVOLUTION | monomer | 99.31 | 1×12P; 1×4G8; | |||
| DISCOVERY OF CELL-ACTIVE PHENYL-IMIDAZOLE PIN1 INHIBITORS BY STRUCTURE-GUIDED FRAGMENT EVOLUTION | monomer | 99.31 | 1×12P; 1×4G5; | |||
| DISCOVERY OF CELL-ACTIVE PHENYL-IMIDAZOLE PIN1 INHIBITORS BY STRUCTURE-GUIDED FRAGMENT EVOLUTION | monomer | 99.31 | 1×12P; 1×4FF; | |||
| human Pin1 Ng mutant | monomer | 100 | 1×PO4; 2×1PE; | |||
| DISCOVERY OF CELL-ACTIVE PHENYL-IMIDAZOLE PIN1 INHIBITORS BY STRUCTURE-GUIDED FRAGMENT EVOLUTION | monomer | 98.62 | 1×12P; 1×4G2; | |||
| Structure-guided design of alpha-amino acid-derived Pin1 inhibitors | monomer | 99.31 | 1×12P; 1×4FI; | |||
| Structure-guided design of alpha-amino acid-derived Pin1 inhibitors | monomer | 98.62 | 1×4C0; 1×12P; | |||
| DISCOVERY OF CELL-ACTIVE PHENYL-IMIDAZOLE PIN1 INHIBITORS BY STRUCTURE-GUIDED FRAGMENT EVOLUTION | monomer | 99.31 | 1×12P; 1×B21; | |||
| DISCOVERY OF CELL-ACTIVE PHENYL-IMIDAZOLE PIN1 INHIBITORS BY STRUCTURE-GUIDED FRAGMENT EVOLUTION | monomer | 99.31 | 1×4F8; 1×12P; | |||
| Crystal structure of Pin1 using laue diffraction | monomer | 99.31 | 1×P3G; | |||
| DISCOVERY OF CELL-ACTIVE PHENYL-IMIDAZOLE PIN1 INHIBITORS BY STRUCTURE-GUIDED FRAGMENT EVOLUTION | monomer | 99.31 | 1×12P; 1×4GE; | |||
| DISCOVERY OF CELL-ACTIVE PHENYL-IMIDAZOLE PIN1 INHIBITORS BY STRUCTURE-GUIDED FRAGMENT EVOLUTION | monomer | 99.31 | 1×12P; 1×4FY; | |||
| Structure-guided design of alpha-amino acid-derived Pin1 inhibitors | monomer | 99.31 | 1×12P; 1×SO4; 1×4BL; | |||
| Discovery of cell-active phenyl-imidazole Pin1 inhibitors by structure-guided fragment evolution | monomer | 99.31 | 1×PE4; 1×ODK; | |||
| Structure-guided design of alpha-amino acid-derived Pin1 inhibitors | monomer | 98.62 | 1×4D9; | |||
| Structure-guided design of alpha-amino acid-derived Pin1 inhibitors | monomer | 99.31 | 1×12P; 1×4DH; | |||
| Crystal Structure Analysis of PIN1 | monomer | 98.26 | 1×TAS; | |||
| Solution structure of the PPIase domain of human Pin1 | monomer | 100 | 1×SO4; | |||
| Structure-Based Design of Novel PIN1 Inhibitors (II) | monomer | 98.23 | 2×GIA; | |||
| Structure of Pin1 PPIase domain bound with all-trans retinoic acid | monomer | 98.23 | 1×REA; | |||
| PPIase in complex with a non-phosphate small molecule inhibitor. | monomer | 98.23 | 1×39X; 1×GOL; | |||
| Structure-Based Design of Novel PIN1 Inhibitors (I) | monomer | 98.23 | ||||
| Structure-Based Design of Novel PIN1 Inhibitors (I) | monomer | 98.23 | 1×J8Z; | |||
| Structure-Based Design of Novel PIN1 Inhibitors (II) | monomer | 98.23 | 1×JZI; | |||
| Structure-guided design of alpha-amino acid-derived Pin1 inhibitors | monomer | 98.23 | 1×4BX; | |||
| Structure-Based Design of Novel PIN1 Inhibitors (I) | monomer | 98.23 | 1×J9Z; | |||
| Solution structure of the Pin1-PPIase (S138A) mutant | monomer | 99.11 | ||||
| Solution structure of the peptidyl prolyl cis-trans isomerase domain of human Pin1 with sulfate ion | monomer | 100 | ||||
| Solution structure of Human Pin1 PPIase C113S mutant | monomer | 99.11 | ||||
| solution structure of human Pin1 PPIase mutant C113A | monomer | 99.11 | ||||
| Solution structure of the peptidyl prolyl cis-trans isomerase domain of C113D mutant human Pin1 wit… | monomer | 99.11 | ||||
| Structure of Pin1 WW domain phospho-mimic S16E | monomer | 97.44 | ||||
| Structure of Pin1 WW domain | monomer | 100 | ||||
| SOLUTION STRUCTURE OF PIN1 WW DOMAIN | monomer | 100 | ||||
| Crystal structure of hPin1 WW domain (5-39) fused with maltose-binding protein | monomer | 100 | 1×GLC; | |||
| NMR solution structure of Pin1 WW domain mutant 5-1 | monomer | 90.91 | ||||
| Protein allostery of the WW domain at atomic resolution: apo structure | monomer | 94.12 | ||||
| Protein allostery of the WW domain at atomic resolution: FFpSPR bound structure | monomer | 94.12 | ||||
| NMR solution structure of Pin1 WW domain mutant 5-1g | monomer | 90.91 | 1×NAG; | |||
| The NMR solution structure of the isolated Apo Pin1 WW domain | monomer | 100 | ||||
| NMR solution structure of Pin1 WW domain mutant 6-1g | monomer | 88.23 | 1×NAG; | |||
| Protein allostery of the WW domain at atomic resolution: pCdc25C bound structure | monomer | 94.12 | ||||
| NMR solution structure of Pin1 WW domain mutant with beta turn mimic at position 12 | monomer | 91.67 | ||||
| NMR solution structure of Pin1 WW domain variant 6-1 | monomer | 88.23 | ||||
| Structure of Pin1 WW Domain Sequence 1 Substituted with [S,S]ACPC | monomer | 96.97 | 2×SO4; | |||
| Structure of Pin1 WW Domain Sequence 3 with [R,R]-ACPC Loop Substitution | monomer | 100 | 1×CL; | |||
| Structure of Pin1 WW Domain Variant 1 with beta3-Ser Loop Substitution | monomer | 100 | 4×CL; | |||
| Structure of racemic Pin1 WW domain cocrystallized with DL-malic acid | monomer | 100 | 1×LMR; | |||
| Structure of racemic Pin1 WW domain cocrystallized with tri-ammonium citrate | monomer | 100 | 1×FLC; | |||
| Crystal structure of hPin1 WW domain (5-21) fused with maltose-binding protein | monomer | 100 | 1×GLC; | |||
| Crystal structure of hPin1 WW domain (5-23) fused with maltose-binding protein | monomer | 100 | 1×GLC; | |||
| Crystal structure of hPin1 WW domain (5-15) fused with maltose-binding protein in C2221 form | monomer | 100 | 1×GLC; | |||
| Crystal structure of hPin1 WW domain (5-15) fused with maltose-binding protein in P41212 form | monomer | 100 | 1×GLC; | |||
4 SWISS-MODEL models
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 2zr4.1.A | monomer | 0.82 | 99.39 | |||
| 1nmv.1.A | monomer | 0.69 | 100.00 | |||
| 7suq.1.A | monomer | 0.55 | 100.00 | |||
| 7sa5.1.A | monomer | 0.54 | 100.00 | |||